1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant
    Meeting Abstract

    Stuver, R.; Mazloom, A.; Ganesan, N.; Horwitz, S. M.; Moskowitz, A. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas
    Meeting Abstract

    Schuster, S. J.; Huw, L. Y.; Bolen, C. R.; Assouline, S. E.; Bartlett, N. L.; Budde, L. E.; Matasar, M. J.; Koeppen, H.; Piccione, E. C.; Wilson, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alliance A059102: A randomized phase II US intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Geyer, S. M.; Barta, S. K.; Amengual, J. E.; Dockter, T.; Wright, C.; Dinner, S.; Hsi, E. D.; Bartlett, N. L.; Horwitz, S. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Izquierdo, A. R.; Martin, E. M. D.; Garcia-Sancho, A. M.; Sandoval-Sus, J. D.; Tilly, H.; Vandenberghe, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Park, S. I.; Phillips, T. J.; Amengual, J.; Andorsky, D. J.; Campbell, P.; McKay, P.; Leonard, J. P.; Sondhi, M.; Yang, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
    Meeting Abstract

    Ansell, S. M.; Connors, J. M.; Radford, J. A.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R. H.; Hutchings, M.; Evens, A. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30
    Meeting Abstract

    Gerlach, M.; Schmitt, S.; Cyprys, P.; Kasper, M. A.; Mai, I.; Vermeer, M. H.; Horwitz, S. M.; Fingerle-Rowson, G.; Vogl, A.; Schumacher, D.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
    Meeting Abstract

    Zain, D. R.; Iyer, S. P.; Sica, R. A.; Ho, P. J.; Hu, B.; Prica, A.; Weng, W. K.; Kim, Y. H.; Khodadoust, M. S.; Palomba, M. L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in (18)F-FDG PET scans of patients with classical Hodgkin lymphoma
    Journal Article

    Driessen, J.; Zwezerijnen, G. J. C.; Schòˆder, H.; Drees, E. E. E.; Kersten, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Eertink, J. J.; de Vet, H. C. W.; Hoekstra, O. S.; more...
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • The international consensus classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee
    Guidelines

    Campo, E.; Jaffe, E. S.; Cook, J. R.; Quintanilla-Martinez, L.; Swerdlow, S. H.; Anderson, K. C.; Brousset, P.; Cerroni, L.; de Leval, L.; Dirnhofer, S.; more...
    Blood (2022)

    Fulltext@MSK | Save